anti-programmed death (ligand)-1 antibody
1 abstract
Abstract
Trends in U.S and global patient enrollment from 2014 to 2022 in lung cancer clinical trials supporting marketing applications: An FDA analysis.Org: Office of Oncologic Diseases, Office of New Drugs, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Oncology Center of Excellence,